iiinova — where your digital self keeps evolving

Reposted by Govind Persad

Hadassa Noorda @hadassanoorda.bsky.social · 21/08/2026

CFA: 2027 Legal Philosophy Workshop at Stanford University, June 17-18, 2027. A great opportunity for scholars at all career stages. Deadline: January 8, 2027. Submit: sites.google.com/site/legalph...

sites.google.com

Legal Philosophy Workshop - CFA for 2027 LPW

We are pleased to announce the 14th annual Legal Philosophy Workshop (LPW), and to invite you to participate. We are excited to host the 2027 workshop in-person on June 17-18 at Stanford University. C...

002

Reposted by Govind Persad

Rachel Sachs @rachelsachs.bsky.social · 05/02/2026

Now up at Health Affairs Forefront, Kristi Martin and I analyze the drugs selected for the 2028 cycle of the Medicare drug price negotiation program. We focus on what will be new this cycle, but also what didn't (but could have) happened this year. www.healthaffairs.org/content/fore...

healthaffairs.org

Analyzing The Drugs Selected For The 2028 Medicare Drug Price Negotiation Cycle | Health Affairs Forefront

The 2028 negotiation cycle marks another major inflection point in the implementation of the Medicare Drug Price Negotiation Program—its first year incorporating Part B drugs and its first opportunity...

021

Govind Persad @govindpersad.bsky.social · 18/04/2024

"Fair Allocation of GLP-1 and Dual GLP-1–GIP Receptor Agonists" is now out in NEJM (w/Zeke Emanuel, Johan Dellgren, Matt McCoy). We propose a #bioethics framework to guide gov'ts, professional societies, & docs in allocation choices about drugs like semaglutide (Ozempic/Wegovy) when demand > supply

nejm.org

Fair Allocation of GLP-1 and Dual GLP-1–GIP Receptor Agonists | NEJM

A shortage of GLP-1 receptor agonists and other drugs raises questions about how limited supplies should be allocated. A proposed framework could guide governments, professional societies, and ...

094

Govind Persad @govindpersad.bsky.social · 24/02/2024

North Carolina & other health systems are being unethical when they categorically refuse to cover GLP-1 receptor agonists (e.g. Ozempic, Mounjaro) for obesity. So I & Zeke Emanuel argue in our Wall Street Journal op-ed. I highlight some of our points below in replies #bioethics

wsj.com

Opinion | For Obese Patients, Wegovy Is Worth the Cost

North Carolina is wrong to deny coverage. Breakthrough treatments curb additional health risks.

1175

Reposted by Govind Persad

Marcel Verweij @marcelverweij.bsky.social · 17/02/2024

…of a paper that determines my judgement of the paper. But the assumptions and starting points of the argument should be reasonable to anyone. In that sense I can offer a fair review of a paper even if the conclusion is something that I deeply disagree with.

151

Reposted by Govind Persad

Marcel Verweij @marcelverweij.bsky.social · 17/02/2024

No, I think value judgements are inevitable, even in the sciences ppl make (epistemic) value judgements all the time - though often implicitly. On top of that It seems impossible to do (and review in) ethics in a morally neutral way. But it should not be my own moral perspective on the conclusion…

142

Govind Persad @govindpersad.bsky.social · 15/02/2024

Revised draft of “Antiracist Medicine in Colorblind Courts,” forthcoming in the Michigan Law Review papers.ssrn.com/sol3/papers.... Added material on new §1981, §1557, & Equal Protection litigation against health & other programs that consider individuals’ race New TX & UT laws are also discussed

Antiracist Medicine in Colorblind Courts

This Article considers how health professionals' efforts to combat racial health inequities interact with legal restrictions constraining their ability to consider race. In light of the Roberts Court's recent invalidation of two university admissions programs, intensifying a "colorblind" judicial shift, the collision between antiracist medicine and colorblind law is a pressing concern. This Article anticipates the implications of this collision and explores how health professionals and systems can design programs that survive judicial examination.

In Part I, the Article examines the frameworks that will apply if antiracist medicine faces legal challenges. These include the Equal Protection Clause and federal statutes like Title VI and Section 1981. Part II systematically outlines three reasons why medicine might consider race: the enhancement of individual and population health through beneficent consideration . . .

141

Govind Persad @govindpersad.bsky.social · 09/02/2024

Thanks to the University of Denver's #RadioEd podcast for featuring my research on healthcare affordability! I analyze health affordability in depth in my "Defining Health Affordability," published (open access) in the Iowa Law Review: ilr.law.uiowa.edu/volume-109-i... #healthlaw #bioethics

du.edu

What Makes American Healthcare (Un)affordable? | University of Denver

University of Denver

065

Govind Persad @govindpersad.bsky.social · 01/02/2024

I was today years old when I learned that Philippa Foot (of trolley problem/virtue ethics fame) was Grover Cleveland’s granddaughter

140

Govind Persad @govindpersad.bsky.social · 31/01/2024

Just listened to interesting Philosophy Bites on transformative experience. Do people really think decisions about whether to become a parent are arational, as opposed to just characterized by imperfect info & value change? Imperfect info, likelihood of change in values ≠ arationality.

000

Govind Persad @govindpersad.bsky.social · 23/01/2024

The Biounethical podcast with Sophie Gibert & @leahpierson.bsky.social has been great listening material for my New Year’s resolution to walk more. Just finished episode w/Danielle Allen on #bioethics & public participation & now in the middle of one with Jeff Sebo on the circle of moral concern

120

Govind Persad @govindpersad.bsky.social · 08/01/2024

I appreciated Robert Califf & Peter Marks at FDA writing on undervaccination and dangers to population immunity But surprised to see not one mention of politics or partisanship as a cause of undervaccination. Curious if they can't say it, or if they don't think it's a cause.

jamanetwork.com

Is Vaccination Approaching a Dangerous Tipping Point?

This Viewpoint discusses declining vaccination rates in the US, specifically against COVID-19, and the ways in which clinicians and the Food and Drug Administra

061

Govind Persad @govindpersad.bsky.social · 18/11/2023

TIL: some believe that if research participants respond regularly & at a high rate to text-message surveys because of: - a motivation to improve the quality of the research output - a desire to be thought well of by the researchers this might be . . . ethically concerning coercion

000

Govind Persad @govindpersad.bsky.social · 01/09/2023

As a fun post-tenure thing, I'm going to try to post favorite health law/policy/bioethics articles on Fridays. Not always ones I perfectly agree with, but ones I've gotten something from. Rules: - Before 2018 - Ideally, not already super famous - Not hard-paywalled

172

Govind Persad @govindpersad.bsky.social · 16/08/2023

Curious (or worried) about how #SCOTUS affirmative action decisions may hamper antiracist efforts in medicine? Happy to share that “Antiracist Medicine in Colorblind Courts” is forthcoming in the Michigan Law Review. Comments welcome! Draft: tinyurl.com/AntiracistMedicine Abstract ⬇

Antiracist Medicine in Colorblind Courts
Michigan Law Review, Forthcoming

53 Pages Posted: 16 Aug 2023
Govind Persad
University of Denver Sturm College of Law

Date Written: August 3, 2023

Abstract
This Article considers how health professionals’ efforts to combat racial health inequities must navigate legal constraints on their ability to consider race. In light of the Roberts Court’s recent invalidation of two university admissions programs, intensifying a “colorblind” judicial shift, the collision between antiracist medicine and colorblind law is a pressing concern. It seeks to anticipate the implications of this collision and explore how health professionals and systems can design programs that survive judicial examination.

In Part I, the Article examines the frameworks that will apply if antiracist medicine faces legal challenges. These include the Equal Protection Clause, federal statutes like Title VI and Section 1981, and state law provisions.

010

Govind Persad @govindpersad.bsky.social · 10/08/2023

[crossposting] I am pleased to share that I’m now (as of Aug. 1) Associate Professor with Tenure at the University of Denver Sturm College of Law. . I’m grateful to the external and internal mentors who supported me through this process, to all my collaborators, and to the outside reviewers.

250